[Early recognition and prevention of schizophrenia and other psychoses].
Früherkennung und Prävention von Schizophrenie und anderen Psychosen
Options
BORIS DOI
Date of Publication
2020
Publication Type
Article
Division/Institute
Contributor
Meisenzahl, E. | |
Walger, P. | |
Koutsouleris, N. | |
Schultze-Lutter, F. |
Series
Der Nervenarzt
ISSN or ISBN (if monograph)
1433-0407
Publisher
Springer
Publisher DOI
PubMed ID
31858162
Description
The last two decades of clinical research have clearly demonstrated the comprehensive benefits of the early recognition and treatment of psychotic disorders. The attenuated and transient positive symptoms according to the ultrahigh risk criteria and the basic symptom criterion “Cognitive disturbances” are the main approaches for an indicated prevention. They have recently been recommended as criteria for a clinical high-risk (CHR) state of psychosis by the European Psychiatric Association (EPA) and, following these, in the German S3 guidelines for the treatment of schizophrenia by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN); however, the efficacy of early treatment of patients with a CHR for psychoses critically depends on the development of prognostic instruments, which enable healthcare professionals to reliably identify these patients based on the individual objective risk profiles. An important goal is the treatment of functional deficits, which can be identified by an individual risk profile. The treatment of existing comorbid mental disorders, psychosocial problems and the prevention of potential future disorders also characterizes the recommendations of the EPA and DGPPN for early treatment, which favor psychotherapeutic, especially cognitive behavioral interventions over pharmacological treatment. The close interdisciplinary cross-sectoral cooperation between the disciplines of child and adolescent psychiatry, and adult psychiatry is of outstanding importance in this context.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| 10.1007@s00115-019-00836-5.pdf | Adobe PDF | 360.61 KB | publisher | published |